Axon Enterprise (AXON) Vs Palantir Technologies (PLTR): Which is the Better Investment?

Axon Enterprise (AXON) and Palantir Technologies (PLTR) both reported robust Q2 results, driven by increased public safety and defense spending, and subsequently raised their full-year guidance. Axon saw Q2 sales rise nearly 33% year-over-year and EPS surge 76%, while Palantir achieved its first-ever billion-dollar quarter with sales up 48%, fueled by strong AI platform demand. Despite Palantir's significant momentum, the analysis suggests Axon is the stronger investment due to its more favorable valuation, trading at 25x forward sales compared to Palantir's 104x, alongside its consistent profitability.

Analysis

Both Axon Enterprise and Palantir Technologies have demonstrated significant operational strength, reporting strong Q2 results and raising full-year guidance, driven by increased public safety and defense spending. Axon posted a 33% year-over-year revenue increase to $668.54 million and a 76% surge in EPS to $2.12, marking its 33rd consecutive quarter of exceeding EPS estimates. Palantir achieved its first billion-dollar quarter with revenue up 48% YoY, fueled by robust demand for its Artificial Intelligence Platform (AIP), particularly from commercial clients, prompting an increase in its commercial revenue guidance to over $1 billion for FY25. The key differentiator for investors lies in valuation. Despite Palantir's superior stock momentum (+130% YTD vs. Axon's +40%), its valuation appears stretched, trading at a forward price-to-sales ratio of 104x. In contrast, Axon trades at a more reasonable 25x forward sales, which, combined with its consistent profitability and higher earnings estimate revisions, positions it as a more fundamentally sound investment according to the analysis.

Key Decisions for Investors

• Given Axon's consistent profitability, 14 consecutive quarters of over 25% revenue growth, and a more justifiable valuation at 25x forward sales, investors may find it a compelling investment case for growth at a reasonable price.
• Investors should be cautious of Palantir's lofty valuation at 104x forward sales, which suggests significant future growth is already priced in; waiting for a pullback or a more attractive entry point could be a prudent strategy despite its strong AI-driven momentum.
• For portfolios balancing growth and value, Axon appears to be the more fundamentally sound option, while momentum-focused investors considering Palantir must acknowledge the high valuation risk following its +130% year-to-date rally.